家族性淀粉样多发性神经病（FAP）市场（2026—2031）
家族性淀粉样多发性神经病（FAP）市场规模预计将从2026年的36.7亿美元增长至2031年的55.6亿美元，预测期复合年增长率为8.66%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
家族性淀粉样多发性神经病（FAP）市场规模预计将从2026年的36.7亿美元增长至2031年的55.6亿美元，预测期复合年增长率为8.66%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 8.66% | 机构预测 |
| 市场规模 | 2026 | USD 3.67 billion | 机构预测 |
| 市场规模 | 2031 | USD 5.56 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_stage | Stage 1 | 2025 | 70.240% |
| distribution_channel | hospital pharmacies | 2025 | 48.140% |
| geography | North America | 2025 | 45.610% |
| modality | treatment | 2025 | 82.310% |
关键结论
- disease_stage 维度中，Stage 1 在 2025 年的公开份额为 70.24%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 48.14%。
- geography 维度中，North America 在 2025 年的公开份额为 45.61%。
- modality 维度中，treatment 在 2025 年的公开份额为 82.31%。
主要参与者
- Alnylam Pharmaceuticals, Inc.
- Pfizer Inc.
- AstraZeneca PLC
- BridgeBio Pharma, Inc.
- Regeneron Pharmaceuticals, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Earlier Genetic Testing and Multisystem Diagnosis | +1.500% | Global, with concentrated early gains in Portugal, Japan, Brazil, and Sweden | Medium term (2-4 years) |
| Expansion of Disease-Modifying Therapy Approvals | +1.800% | Global, with early gains in North America and the EU, followed by Asia-Pacific and Latin America | Short term (≤ 2 years) |
| Growing RNA-Silencer Adoption | +1.200% | North America and the EU, with growing use in Asia-Pacific and Latin America | Medium term (2-4 years) |
| Expansion of Specialist Amyloidosis Centers | +0.800% | Endemic regions, with early gains in Porto, Lisbon, Tokyo, Nagoya, and São Paulo | Long term (≥ 4 years) |
| Family Cascade Testing in Endemic Variant Clusters | +0.700% | Portugal, Sweden, Japan, Brazil, South Korea, and Taiwan | Medium term (2-4 years) |
| Monthly and Quarterly Self-Administration: Shifting the Site of Care | +0.600% | North America and the EU, with expansion to Australia and Japan | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Ultra-High Treatment Cost and Reimbursement Friction | -1.000% | Global, most acute in EU member states, Japan, and emerging markets | Medium term (2-4 years) |
| Regulatory, Safety-Monitoring, and Vitamin A Management Requirements | -0.700% | Global, with the greatest burden where rare-disease infrastructure is limited | Short term (≤ 2 years) |
| Genotype and Phenotype Heterogeneity Complicating Endpoint Design | -0.500% | Global, primarily non-endemic regions with diverse variant profiles | Long term (≥ 4 years) |
| Limited Infusion, Genetic-Counseling, and Rare-Disease Laboratory Capacity | -0.400% | Asia-Pacific outside Japan and Australia, the Middle East and Africa, and parts of Latin America | Long term (≥ 4 years) |
报告关注的关键问题
What is the familial amyloid polyneuropathy market size?
The familial amyloid polyneuropathy market size is USD 3.67 billion in 2026 and is forecast to reach USD 5.56 billion by 2031 at an 8.66% CAGR.
What is driving demand for familial amyloid polyneuropathy treatments?
New disease-modifying approvals, greater RNA-silencer use, earlier genetic testing, and family-cascade programs are widening treatment access.
Which treatment modality has the largest position?
Treatment held 82.31% share in 2025, supported by transthyretin stabilizers and RNA-silencing therapies.
Which patient group is growing fastest?
Presymptomatic pathogenic TTR-variant carriers are forecast to grow at a 12.22% CAGR through 2031 as family-cascade testing expands.
Which region is growing fastest for familial amyloid polyneuropathy?
Asia-Pacific is forecast to grow at an 11.25% CAGR through 2031, supported by structured care pathways and expanded therapy access.
What is the main barrier to treatment access?
Annual list prices ranging from USD 244,000 to USD 464,000 and evidence-based reimbursement requirements remain major barriers.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence